Gerald T. Proehl
CIK: 0001279191
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Aug 16, 2026DRMA
Dermata Therapeutics, Inc.
Award(A)Indirect170.1K shares- - Jan 9, 2026TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
3K shares- - Jan 2, 2026DRMA
Dermata Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
37.5K shares- - Dec 23, 2025DRMA
Dermata Therapeutics, Inc.
Award(A)Indirect490.2K shares- - Dec 23, 2025DRMA
Dermata Therapeutics, Inc.
Award(A)Indirect122.5K shares- - Dec 23, 2025DRMA
Dermata Therapeutics, Inc.
Disposition(D)DirectWarrant (Right to Buy)
78.7K shares- - Jul 1, 2025TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
80K shares- - Jan 21, 2025DRMA
Dermata Therapeutics, Inc.
Award(A)Indirect787.4K shares- - Jan 13, 2025DRMA
Dermata Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Dec 10, 2024TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 16, 2026 |  DRMA Dermata Therapeutics, Inc. | Award(A) | 170,068 | - | $0 | Indirect |
| Jan 9, 2026 |  TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 3,000 | - | - | Direct |
| Jan 2, 2026 | DRMA Dermata Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 37,500 | - | - | Direct |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | Award(A) | 490,196 | - | - | Indirect |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | Award(A) | 122,549 | - | - | Indirect |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | Disposition(D) Warrant (Right to Buy) | 78,740 | - | - | Direct |
| Jul 1, 2025 | TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 80,000 | - | - | Direct |
| Jan 21, 2025 | DRMA Dermata Therapeutics, Inc. | Award(A) | 787,402 | - | $0 | Indirect |
| Jan 13, 2025 | DRMA Dermata Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Dec 10, 2024 | TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
1-10 of 10 transactions
About PROEHL GERALD T
PROEHL GERALD T (SEC CIK 0001279191) files insider reports with the SEC as PRESIDENT, CHAIRMAN, CEO of Dermata Therapeutics, Inc. (DRMA) and Director of TENAX THERAPEUTICS, INC. (TENX).
Signal8 holds 8 ownership filings by PROEHL GERALD T, all Form 4s, filed between Dec 12, 2024 and Aug 18, 2026. Those filings report 10 transactions, from Dec 10, 2024 to Aug 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on PROEHL GERALD T's filings is in SAN DIEGO, CA.
Recent filings by PROEHL GERALD T
- Aug 16, 2026: Grant or award of DRMA shares (Form 4, code A).
- Jan 9, 2026: Grant or award of TENX derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of DRMA derivative securities (Form 4, code A).
- Dec 23, 2025: Grants or awards of DRMA shares (2 lines, Form 4, code A).
- Dec 23, 2025: Disposition to issuer transaction of DRMA derivative securities (Form 4, code D).
Other insiders filing for Dermata Therapeutics, Inc. (DRMA)
- Van Hoose Kyri K., SVP, CFO
- Scott Kathleen D., Director
- Bedoya-Toro Munera Maria E, SVP, Regulatory Affairs
- WIERENGA WENDELL, Director
- HALE DAVID F, Director
- Nardo Christopher J., Senior VP, CDO